Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.275 USD | +0.08% | -1.42% | -28.51% |
27/03 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
27/03 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.